Recognition of cisplatin adducts by cellular proteins.

Cisplatin is a widely used chemotherapeutic agent. It reacts with nucleophilic bases in DNA and forms 1,2-d(ApG), 1,2-d(GpG) and 1,3-d(GpTpG) intrastrand crosslinks, interstrand crosslinks and monofunctional adducts. The presence of these adducts in DNA is through to be responsible for the therapeutic efficacy of cisplatin. The exact signal transduction pathway that leads to cell cycle arrest and cell death following treatment with the drug is not known but cell death is believed to be mediated by the recognition of the adducts by cellular proteins. Here we describe the structural information available for cisplatin and related platinum adducts, the interactions of the adducts with cellular proteins and the implications of these interactions for cell survival.

[1]  S. Lippard,et al.  Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities. , 1998, Biochemistry.

[2]  P. Beaune,et al.  A single d(GpG) cisplatin adduct on the estrogen response element decreases the binding of the estrogen receptor , 2000, FEBS letters.

[3]  C. Rudolph,et al.  The High Mobility Group Domain Protein Cmb1 ofSchizosaccharomyces pombe Binds to Cytosines in Base Mismatches and Opposite Chemically Altered Guanines* , 1998, The Journal of Biological Chemistry.

[4]  S. Lippard,et al.  Repair of cisplatin--DNA adducts by the mammalian excision nuclease. , 1996, Biochemistry.

[5]  P. Lohman,et al.  Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. , 1985, Biochemistry.

[6]  M. Hawn,et al.  Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. , 1995, Cancer research.

[7]  T. Kunkel,et al.  The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. , 1998, Cancer research.

[8]  M. Marinus,et al.  Studies on mutagenesis and repair induced by platinum analogs. , 1986, Mutation research.

[9]  P. Billings,et al.  Purification of nuclear proteins that bind to cisplatin-damaged DNA. Identity with high mobility group proteins 1 and 2. , 1992, The Journal of biological chemistry.

[10]  J. Yu,et al.  Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. , 1994, The Journal of clinical investigation.

[11]  P. Jordan,et al.  Cisplatin inhibits synthesis of ribosomal RNA in vivo. , 1998, Nucleic acids research.

[12]  W. Plunkett,et al.  Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro. , 1997, Cancer research.

[13]  L. Pearl,et al.  Crystal Structure of a G:T/U Mismatch-Specific DNA Glycosylase Mismatch Recognition by Complementary-Strand Interactions , 1998, Cell.

[14]  G. Raaphorst,et al.  Modulation of radiation-induced strand break repair by cisplatin in mammalian cells. , 1998, International journal of radiation biology.

[15]  S K Burley,et al.  Crystal structure of a human TATA box-binding protein/TATA element complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  G. Chu,et al.  A novel role for DNA photolyase: binding to DNA damaged by drugs is associated with enhanced cytotoxicity in Saccharomyces cerevisiae. , 1994, Molecular and cellular biology.

[17]  K. Kohno,et al.  Direct Involvement of the Y-box Binding Protein YB-1 in Genotoxic Stress-induced Activation of the Human Multidrug Resistance 1 Gene* , 1998, The Journal of Biological Chemistry.

[18]  G. Chu,et al.  Xeroderma pigmentosum group E binding factor recognizes a broad spectrum of DNA damage. , 1994, Mutation research.

[19]  R. Bristow,et al.  Mutator phenotype in Msh2-deficient murine embryonic fibroblasts. , 1997, Cancer research.

[20]  S. Lippard,et al.  Bending studies of DNA site-specifically modified by cisplatin, trans-diamminedichloroplatinum(II) and cis-[Pt(NH3)2(N3-cytosine)Cl]+. , 1990, Biophysical chemistry.

[21]  K. Tanaka,et al.  The XPA protein is a zinc metalloprotein with an ability to recognize various kinds of DNA damage. , 1994, Mutation research.

[22]  P. Modrich,et al.  Cisplatin and Adriamycin Resistance Are Associated with MutLα and Mismatch Repair Deficiency in an Ovarian Tumor Cell Line* , 1996, The Journal of Biological Chemistry.

[23]  James Allan,et al.  3‐methyladenine DNA glycosylases: structure, function, and biological importance , 1999, BioEssays : news and reviews in molecular, cellular and developmental biology.

[24]  J. Turchi,et al.  Replication Protein A (RPA) Binding to Duplex Cisplatin-damaged DNA Is Mediated through the Generation of Single-stranded DNA* , 1999, The Journal of Biological Chemistry.

[25]  K. V. van Holde,et al.  The major chromatin protein histone H1 binds preferentially to cis-platinum-damaged DNA. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[26]  P. Lohman,et al.  The quantitative detection of various Pt-DNA-adducts in Chinese hamster ovary cells treated with cisplatin: application of immunochemical techniques. , 1985, Carcinogenesis.

[27]  S. Lippard,et al.  Isolation of cDNAs encoding a human protein that binds selectively to DNA modified by the anticancer drug cis-diamminedichloroplatinum(II) , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Leng,et al.  Distortions induced in double-stranded oligonucleotides by the binding of cis- or trans-diammine-dichloroplatinum(II) to the d(GTG) sequence. , 1990, Nucleic acids research.

[29]  L. Samson,et al.  Crystal Structure of a Human Alkylbase-DNA Repair Enzyme Complexed to DNA Mechanisms for Nucleotide Flipping and Base Excision , 1998, Cell.

[30]  J. Turchi,et al.  Human Ku Autoantigen Binds Cisplatin-damaged DNA but Fails to Stimulate Human DNA-activated Protein Kinase* , 1996, The Journal of Biological Chemistry.

[31]  S. Lippard,et al.  HMG domain proteins induce sharp bends in cisplatin-modified DNA. , 1994, Biochemistry.

[32]  R. Wood,et al.  Preferential binding of the xeroderma pigmentosum group A complementing protein to damaged DNA. , 1993, Biochemistry.

[33]  R. Wood,et al.  Open complex formation around a lesion during nucleotide excision repair provides a structure for cleavage by human XPG protein , 1997, The EMBO journal.

[34]  D. Moras,et al.  Cisplatin‐ and UV‐damaged DNA lure the basal transcription factor TFIID/TBP , 1997, The EMBO journal.

[35]  S. Aebi,et al.  Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. , 1997, Cancer research.

[36]  G. Marsischky,et al.  Redundancy of Saccharomyces cerevisiae MSH3 and MSH6 in MSH2-dependent mismatch repair. , 1996, Genes & development.

[37]  V. Brabec,et al.  DNA interstrand cross-links of trans-diamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[38]  S. Lippard,et al.  HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[39]  C. Rawlings,et al.  Increased sensitivity of UV-repair-deficient human cells to DNA bound platinum products which unlike thymine dimers are not recognized by an endonuclease extracted from Micrococcus luteus. , 1978, Mutation research.

[40]  G. Sancar,et al.  Evidence for Dinucleotide Flipping by DNA Photolyase* , 1998, The Journal of Biological Chemistry.

[41]  J. Trosko,et al.  Platinum Compounds: a New Class of Potent Antitumour Agents , 1969, Nature.

[42]  J. Turchi,et al.  Human replication protein A preferentially binds cisplatin-damaged duplex DNA in vitro. , 1998, Biochemistry.

[43]  S. Keeney,et al.  Correction of the DNA repair defect in xeroderma pigmentosum group E by injection of a DNA damage-binding protein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. Leng,et al.  Base sequence-independent distorsions induced by interstrand cross-links in cis-diamminedichloroplatinum (II)-modified DNA. , 1994, Nucleic acids research.

[45]  D. S. Hsu,et al.  The other function of DNA photolyase: stimulation of excision repair of chemical damage to DNA. , 1995, Biochemistry.

[46]  Antonio Costanzo,et al.  The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage , 1999, Nature.

[47]  C. Boland,et al.  Loss of DNA mismatch repair in acquired resistance to cisplatin. , 1996, Cancer research.

[48]  R. Wood,et al.  Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours , 1999, Current Biology.

[49]  G. Chu,et al.  Xeroderma pigmentosum group E cells lack a nuclear factor that binds to damaged DNA. , 1988, Science.

[50]  A. Wang,et al.  Solution structure of a DNA duplex containing a cis-diammineplatinum(II) 1,3-d(GTG) intrastrand cross-link, a major adduct in cells treated with the anticancer drug carboplatin. , 1999, Biochemistry.

[51]  R. Alazard,et al.  Mechanism of toxicity of platinum(II) compounds in repair-deficient strains of Escherichia coli , 1982 .

[52]  A. Eastman.  Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum(II). , 1983, Biochemistry.

[53]  C. Pabo,et al.  Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins , 1999, Nature.

[54]  C. J. V. Garderen,et al.  The Solution Structure of a DNA Duplex Containing the cis ‐Pt(NH3)2[d(‐GTG‐)‐N 7(G), N 7(G)] Adduct, as Determined with High‐Field NMR and Molecular Mechanics/Dynamics , 1994 .

[55]  A. Sancar,et al.  Reactions of the UVRABC excision nuclease with DNA damaged by diamminedichloroplatinum(II). , 1985, Nucleic acids research.

[56]  S. Lippard,et al.  The HMG-domain protein Ixr1 blocks excision repair of cisplatin-DNA adducts in yeast. , 1996, Mutation research.

[57]  W. de Laat,et al.  DNA-binding polarity of human replication protein A positions nucleases in nucleotide excision repair. , 1998, Genes & development.

[58]  B. Viollet,et al.  TATA Binding Protein Discriminates between Different Lesions on DNA, Resulting in a Transcription Decrease , 1998, Molecular and Cellular Biology.

[59]  D. Nagel,et al.  Characterization of bifunctional adducts produced in DNA by trans-diamminedichloroplatinum(II). , 1988, Chemico-biological interactions.

[60]  J. Essigmann,et al.  Cisplatin adducts inhibit 1,N(6)-ethenoadenine repair by interacting with the human 3-methyladenine DNA glycosylase. , 2000, Biochemistry.

[61]  J. Turchi,et al.  Interactions of mammalian proteins with cisplatin-damaged DNA. , 1999, Journal of inorganic biochemistry.

[62]  J. Wang,et al.  Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells , 1999, British Journal of Cancer.

[63]  P. Karran,et al.  Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins. , 1997, Nucleic acids research.

[64]  D. Housman,et al.  Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[65]  A. Gronenborn,et al.  NMR spectroscopic analysis of the DNA conformation induced by the human testis determining factor SRY. , 1995, Biochemistry.

[66]  A. V. van Oosterom,et al.  cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II). , 1987, Cancer research.

[67]  W. Shepard,et al.  Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63 A resolution: hydration at the platinated site. , 1999, Nucleic acids research.

[68]  A. Wang,et al.  Structure and isomerization of an intrastrand cisplatin-cross-linked octamer DNA duplex by NMR analysis. , 1995, Biochemistry.

[69]  M. Leng,et al.  NMR solution structure of a DNA decamer containing an interstrand cross-link of the antitumor drug cis-diamminedichloroplatinum (II). , 1996, Journal of biomolecular structure & dynamics.

[70]  Steven Hahn,et al.  Crystal structure of a yeast TBP/TATA-box complex , 1993, Nature.

[71]  David A. Case,et al.  Structural basis for DNA bending by the architectural transcription factor LEF-1 , 1995, Nature.

[72]  J. Bourhis,et al.  Cross-resistance to ionizing radiation in a murine leukemic cell line resistant to cis-dichlorodiammineplatinum(II): role of Ku autoantigen. , 1999, Molecular pharmacology.

[73]  M. Meuth,et al.  Mutator phenotypes in human colorectal carcinoma cell lines. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[74]  B. D. de Grooth,et al.  DNA bending by photolyase in specific and non-specific complexes studied by atomic force microscopy. , 1999, Nucleic acids research.

[75]  R Grosschedl,et al.  HMG domain proteins: architectural elements in the assembly of nucleoprotein structures. , 1994, Trends in genetics : TIG.

[76]  G. Chu,et al.  Evidence that xeroderma pigmentosum cells from complementation group E are deficient in a homolog of yeast photolyase , 1989, Molecular and cellular biology.

[77]  A. V. D. Van Der Zee,et al.  hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents , 1997, Oncogene.

[78]  R. Brown,et al.  Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. , 1996, Cancer research.

[79]  D. Housman,et al.  Isolation and characterization of cDNA clones encoding the Drosophila homolog of the HMG-box SSRP family that recognizes specific DNA structures. , 1993, Nucleic acids research.

[80]  A. Gronenborn,et al.  Molecular basis of human 46X,Y sex reversal revealed from the three-dimensional solution structure of the human SRY-DNA complex , 1995, Cell.

[81]  D. Job,et al.  RNA polymerases react differently at d(ApG) and d(GpG) adducts in DNA modified by cis-diamminedichloroplatinum(II). , 1992, Biochemistry.

[82]  V. Brabec,et al.  Recognition of DNA interstrand cross-links of cis-diamminedichloroplatinum(II) and its trans isomer by DNA-binding proteins. , 1995, Biochemistry.

[83]  R. Wood,et al.  Enhancement of damage-specific DNA binding of XPA by interaction with the ERCC1 DNA repair protein. , 1995, Biochemical and biophysical research communications.

[84]  V. Torri,et al.  Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. , 1997, Gynecologic oncology.

[85]  Stephen K. Burley,et al.  Co-crystal structure of TBP recognizing the minor groove of a TATA element , 1993, Nature.

[86]  S. Lippard,et al.  Enhanced binding of the TATA-binding protein to TATA boxes containing flanking cisplatin 1,2-cross-links. , 2000, Biochemistry.

[87]  T. Boulikas.  DNA lesion-recognizing proteins and the p53 connection. , 1996, Anticancer research.

[88]  S. Lippard,et al.  Binding of Ixr1, a yeast HMG-domain protein, to cisplatin-DNA adducts in vitro and in vivo. , 1996, Biochemistry.

[89]  G. Gale,et al.  Cis-dichlorodiammineplatinum (II). Persistent and selective inhibition of deoxyribonucleic acid synthesis in vivo. , 1970, Biochemical pharmacology.

[90]  D. R. Duckett,et al.  Recognition and repair of compound DNA lesions (base damage and mismatch) by human mismatch repair and excision repair systems , 1997, Molecular and cellular biology.

[91]  F. Allain,et al.  Solution structure of the HMG protein NHP6A and its interaction with DNA reveals the structural determinants for non‐sequence‐specific binding , 1999, The EMBO journal.

[92]  K. Comess,et al.  Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts. , 1992, Biochemistry.

[93]  P. Frit,et al.  UV sensitivity and impaired nucleotide excision repair in DNA-dependent protein kinase mutant cells. , 1998, Nucleic acids research.

[94]  C. Macleod,et al.  In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. , 1997, Cancer research.

[95]  A. Travers,et al.  HMG‐D is an architecture‐specific protein that preferentially binds to DNA containing the dinucleotide TG. , 1995, The EMBO journal.

[96]  S. Lippard,et al.  Biological Processing of DNA Modified by Platinum Compounds , 1991 .

[97]  R. Brubaker,et al.  Effect of cis-Platinum(II)Diamminodichloride on Wild Type and Deoxyribonucleic Acid Repair-Deficient Mutants of Escherichia coli , 1973, Journal of bacteriology.

[98]  S. Lippard,et al.  DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II). , 1991, Biochemistry.

[99]  D. K. Treiber,et al.  Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[100]  S. Lippard,et al.  Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. , 1993, Science.

[101]  R. Wood,et al.  Relationship of the Xeroderma Pigmentosum Group E DNA Repair Defect to the Chromatin and DNA Binding Proteins UV-DDB and Replication Protein A , 1998, Molecular and Cellular Biology.

[102]  P. Donahoe,et al.  An SRY mutation causing human sex reversal resolves a general mechanism of structure-specific DNA recognition: application to the four-way DNA junction. , 1995, Biochemistry.

[103]  S. Lippard,et al.  Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. , 1992, Science.

[104]  A. Eastman.  Interstrand cross-links and sequence specificity in the reaction of cis-dichloro(ethylenediamine)platinum(II) with DNA. , 1985, Biochemistry.

[105]  C. Welsch.  Growth inhibition of rat mammary carcinoma induced by cis-platinum diamminodichloride-II. , 1971, Journal of the National Cancer Institute.

[106]  P. Modrich,et al.  Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells. , 1995, Science.

[107]  D. K. Treiber,et al.  Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin. , 1990, Biochemistry.

[108]  S. Lippard,et al.  Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin , 1995, Nature.

[109]  J. Essigmann,et al.  Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor. , 1998, Biochemistry.

[110]  W. Thilly,et al.  Isolation and partial characterization of human cell mutants differing in sensitivity to killing and mutation by methylnitrosourea and N-methyl-N'-nitro-N-nitrosoguanidine. , 1986, The Journal of biological chemistry.

[111]  S. Aebi,et al.  The role of DNA mismatch repair in platinum drug resistance. , 1996, Cancer research.

[112]  M. Li,et al.  Cisplatin-DNA binding specificity of calf high-mobility group 1 protein. , 1996, Biochemistry.

[113]  M. Tanimoto,et al.  Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. , 1996, Cancer research.

[114]  A. Sancar,et al.  Replication Protein A Confers Structure-specific Endonuclease Activities to the XPF-ERCC1 and XPG Subunits of Human DNA Repair Excision Nuclease (*) , 1996, The Journal of Biological Chemistry.

[115]  K. Akuta,et al.  The Number of Platinum Atoms Binding to DNA, RNA and Protein Molecules of HeLa Cells Treated with Cisplatin at Its Mean Lethal Concentration , 1992, Japanese journal of cancer research : Gann.

[116]  G. Chu,et al.  Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[117]  A. Eastman,et al.  Interaction of trans-diamminedichloroplatinum(II) with DNA: formation of monofunctional adducts and their reaction with glutathione. , 1987, Biochemistry.

[118]  BARNETT ROSENBERG,et al.  Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode , 1965, Nature.

[119]  S. Lippard,et al.  Crystal Structure of the Anticancer Drug Cisplatin Bound to Duplex DNA , 1996 .

[120]  K. McLaughlin,et al.  Binding of human single-stranded DNA binding protein to DNA damaged by the anticancer drug cis-diamminedichloroplatinum (II). , 1992, Cancer research.

[121]  D. Crothers,et al.  The major adduct of the antitumor drug cis-diamminedichloroplatinum(II) with DNA bends the duplex by approximately equal to 40 degrees toward the major groove. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[122]  S. Lippard,et al.  Binding of tsHMG, a mouse testis-specific HMG-domain protein, to cisplatin-DNA adducts. , 1997, Biochemistry.

[123]  V. Bohr,et al.  ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. , 1992, Journal of the National Cancer Institute.

[124]  H. Uchino,et al.  Effects of anticancer platinum compounds on Escherichia coli strains with normal and defective DNA repair capacity. , 1981, Gan.

[125]  M. Boudvillain,et al.  NMR solution structure of a DNA dodecamer containing a transplatin interstrand GN7-CN3 cross-link. , 1999, Nucleic acids research.

[126]  G. Krauss,et al.  Photocrosslinking locates a binding site for the large subunit of human replication protein A to the damaged strand of cisplatin-modified DNA. , 1999, Nucleic acids research.

[127]  D. Lilley,et al.  Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[128]  S. Popoff,et al.  Repair of plasmid DNA damaged in vitro with cis- or trans-diamminedichloroplatinum(II) in Escherichia coli. , 1987, Mutation research.

[129]  Christopher A. Lepre,et al.  Platinum-195 NMR kinetic and mechanistic studies of cis- and trans-diamminedichloroplatinum(II) binding to DNA , 1990 .

[130]  P. J. Abrahams,et al.  Host-cell reactivation of cis-diamminedichloroplatinum(II)-treated SV40 DNA in normal human, Fanconi anaemia and xeroderma pigmentosum fibroblasts. , 1984, Mutation research.

[131]  M. Leng,et al.  Conformation of DNA modified at a d(GG) or a d(AG) site by the antitumor drug cis-diamminedichloroplatinum(II). , 1989, Biochemistry.

[132]  R. Ozols,et al.  Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. , 1986, The Journal of clinical investigation.

[133]  J. Roberts,et al.  Interactions between mammalian cell DNA and inorganic platinum compounds. I. DNA interstrand cross-linking and cytotoxic properties of platinum(II) compounds. , 1974, Biochemical pharmacology.

[134]  A J Thomson,et al.  The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum(IV) complexes. , 1967, The Journal of biological chemistry.

[135]  M. Yamada,et al.  Differential human nucleotide excision repair of paired and mispaired cisplatin-DNA adducts. , 1997, Nucleic acids research.

[136]  S. Chaney,et al.  Induction of UV-damage recognition protein by cisplatin treatment. , 1995, Biochemistry.

[137]  R. Davis,et al.  Characterization of high mobility group protein binding to cisplatin-damaged DNA. , 1992, Biochemical and biophysical research communications.

[138]  J. Turchi,et al.  Mechanism of DNA-dependent protein kinase inhibition by cis-diamminedichloroplatinum(II)-damaged DNA. , 1997, Biochemistry.

[139]  J. Roberts,et al.  Interactions between mammalian cell DNA and inorganic platinum compounds. II. Interstrand cross-linking of isolated and cellular DNA by platinum(IV) compounds. , 1974, Biochemical pharmacology.

[140]  J. Hoeschele,et al.  Kinetic analysis of the in vitro binding of radioactive cis- and trans-dichlorodiammineplatinum(II) to DNA. , 1980, Chemico-biological interactions.

[141]  S. Lippard,et al.  Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. , 1985, Biochimica et biophysica acta.

[142]  S. Lippard,et al.  NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin. , 1998, Biochemistry.

[143]  J. Essigmann,et al.  The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. , 1996, Chemistry & biology.

[144]  S. Lippard,et al.  Stopped-flow fluorescence studies of HMG-domain protein binding to cisplatin-modified DNA. , 2000, Biochemistry.

[145]  S. Lippard,et al.  DNA sequence context and protein composition modulate HMG-domain protein recognition of cisplatin-modified DNA. , 1997, Biochemistry.

[146]  K. Tanaka,et al.  Identification of a damaged-DNA binding domain of the XPA protein. , 1996, Mutation research.

[147]  J. Reedijk,et al.  Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. , 1988, Cancer research.

[148]  J. Jiricny,et al.  hMutSβ, a heterodimer of hMSH2 and hMSH3, binds to insertion/deletion loops in DNA , 1996, Current Biology.

[149]  R. Kociba,et al.  Inhibition of Dunning asc itic leukemia and Walker 256 carcinosarcoma with cis-diamminedichloroplatinum (NSC-119875). , 1970, Cancer chemotherapy reports.

[150]  G. Marsischky,et al.  hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[151]  A. Sancar,et al.  Escherichia coli DNA photolyase stimulates uvrABC excision nuclease in vitro. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[152]  S. Lippard,et al.  195Pt NMR Kinetic and Mechanistic Studies of cis- and trans-Diamminedichloroplatinum(II) Binding to DNA. , 1990 .

[153]  G. Pfeifer,et al.  3-Methyladenine-DNA Glycosylase (MPG Protein) Interacts with Human RAD23 Proteins* , 2000, The Journal of Biological Chemistry.

[154]  H. Takano,et al.  Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. , 1999, Cancer research.

[155]  D. Lilley,et al.  T4 endonuclease VII cleaves DNA containing a cisplatin adduct. , 1993, Journal of molecular biology.

[156]  S. Lippard,et al.  Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[157]  Huifang Huang,et al.  Solution Structure of a Cisplatin-Induced DNA Interstrand Cross-Link , 1995, Science.